Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.…
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Immunovant (NASDAQ: IMVT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 315 employees.
The shares were at 31.77 USD on 20 November 2026, up 36.1% over 52 weeks. Its 52-week range is 21.43 USD to 45.35 USD: the price is 29.9% below the high and 48.3% above the low.
Its market capitalisation is 6.57B USD.
Immunovant reports return on equity of -59.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 722.27M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Buy; their mean price target of 48.63 USD is 53.1% above the current price. The next earnings report is expected on 5 February 2027.